1Esehbach JW,E grie J,D own MR, et al. Correction of the an em ia o f end stage renal disease with recombinant human ery tb ro pi oe nn,resu|to fa e ombined phasea nde linicalt rial[J].Ne w E ng lj bled.1987,316(1);73-78. 被引量：1
2VaziriN D.M echanism ofc rythorpoietin-induced hypertension [J] . A m l K idney Dis,1999.33(5):821-828. 被引量：1
5ParkerK P,Mitch WE,S tivelman JC,eta l. Safety and efficacy of low do ses ubcutaneouse rythropoletini n hemodialysisp atients E1 l JA m S - Nephr. 1,1997,8(5): 288-293. 被引量：1
5Koury ST, Koury MJ. Erythropoietin production by the kidney. Semin Nephrol, 1993,13(1):78-86. 被引量：1
6Eckardt KU. Erythropoietin: oxygen - dependent control of erythropoiesis and its failure inrenal disease. Nephron, 1994,67(1):7- 23. 被引量：1
7Sasaki R,Masuda S,Nagao M.Erythropoietin:multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem,2000,64(9): 1775 - 93. 被引量：1
8Yoshioka K, Fisher JW. Nitric oxide enhancement of erythropoietin production in the isolated perfused rat kidney. Am J Physiol,1995,269(4 Pt 1):C917-22. 被引量：1
